Ondine Biomedical Inc. Expands into ICU Market with Steriwave®

Ondine Biomedical Inc. is poised to enter the Intensive Care Unit (ICU) market in Canada, aiming to address a significant opportunity for its light-activated antimicrobial treatment, Steriwave®. This expansion is fueled by Canadian hospitals' growing interest and the potential to drastically increase the market for Steriwave®. With hundreds of thousands of patients admitted to ICUs annually in Canada, Ondine's focus is on preventing infections unrelated to their primary medical condition, offering a promising outlook for both patient health and hospital cost savings.

Utilizing Steriwave® in ICUs could lead to substantial reductions in healthcare-associated infections (HAIs), which have been known to extend hospital stays significantly, thereby escalating healthcare costs. Based on past studies, Ondine anticipates that Steriwave® will not only reduce ICU-related infections but also lead to notable savings for hospitals due to shorter hospital stays and lower resultant health costs. Furthermore, with increasing resistance to traditional antibiotics like mupirocin, Steriwave® presents a viable alternative that does not contribute to antimicrobial resistance (AMR).

Steriwave® operates through a photosensitizer and red light activation to eliminate harmful pathogens, distinguishing itself by not triggering AMR. It has received regulatory approvals across Canada, the UK, the EU, and Mexico for ICU use. As Ondine Biomedical ventures into the ICU market, it leverages existing sales and marketing infrastructure for an efficient expansion, underlining a strategic move to widen its market presence and address a critical area of hospital care.